Thrombotic Thrombocytopenic Purpura and Heparin-Induced Thrombocytopenia: Two Unique Causes of Life-Threatening Thrombocytopenia

Clinics in Laboratory Medicine

Volumn 29, Issue 2, 2009, Pages 321-338

  Marques, Marisa B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Heparin; HIT; Plasma exchange; Thrombocytopenia; TTP

Indexed keywords

ANTICOAGULANT AGENT; CYCLOSPORIN; GLUCOCORTICOID; HEPARIN; RITUXIMAB; VINCRISTINE;

CLINICAL FEATURE; FEVER; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; LABORATORY TEST; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SYMPTOM; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; FEMALE; HEPARIN; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; PLASMA EXCHANGE; PLATELET FUNCTION TESTS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK FACTORS; THROMBOCYTOPENIA;

EID: 68149171773     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.03.003     Document Type: Review

References (69)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 24 (1924) 21-24
2. Bukowski R.M., King J.W., and Hewlett J.S. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 50 (1977) 413-417
3. Moake J.L., Rudy C.K., Troll J.H., et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307 (1982) 1432-1435
4. Furlan M., Robles R., Galbusera M., et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998) 1578-1584
5. Tsai H.M., and Lian E.C. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998) 1585-1594
6. Rock G., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325 (1991) 393-397
7. Arya M., Anvari B., Romo G.M., et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 99 (2002) 3971-3977
8. Zheng X., Chung C., Takayama T.K., et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 (2001) 41059-41063
9. Veyradier A., Obert B., Houllier A., et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98 (2002) 1765-1772
10. Sadler J.E., Moake J.L., Myata T., et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2004) 407-423
11. George J.N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 96 (2000) 1223-1229
12. Crowther M.A., and George J.N. Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med 75 (2008) 369-375
13. Tuncer H.H., Oster R.A., Huang S.T., et al. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion 47 (2007) 107-114
14. Staropoli J.F., Stowell C.P., Tuncer H.H., et al. An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura. Vox Sang 96 (2009) 344-348
15. Park Y.A., Waldrum M.R., and Marques M.B. Common assays distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and disseminated intravascular coagulation. Transfusion 46 Suppl (2006) 4A
16. Hughes C., McEwan J.R., Longair I., et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost 7 (2009) 529-536
17. Scully M., Yarranton R., Liesner R., et al. Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142 (2008) 819-826
18. Tsai H.M. High titers of inhibitors of von Willebrand factor cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 65 (2000) 251-255
19. Vesely S.K., George J.N., Lammle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102 (2003) 60-68
20. Bohm M., Betz C., Miesbach W., et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 129 (2005) 644-652
21. Szczepiorkowski Z.M., Bandarenko N., Kim H.C., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher 22 (2007) 106-175
22. Nicol K.K., Shelton B.J., Knovich M.A., et al. Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura. Am J Hematol 74 (2003) 170-174
23. Dervenoulas J., Tsirigotis P., Bollas G., et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 79 (2000) 66-72
24. Lakey M.A., Boctor F.N., Knight C.S., et al. VWF-cleaving protease activity and inhibitor levels do not predict duration of treatment in TTP and HUS. J Clin Apher 20 (2005) 7
25. Torok T.J., Holman R.C., and Chorba T.L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968-1991. Am J Hematol 50 (1995) 84-90
26. George J.N., Woodson R.D., Kiss J.E., et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21 (2006) 49-56
27. Swisher K.K., Terrell D.R., Vesely S.K., et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion (2009) in press
28. Weismann R.E., and Tobin R.W. Arterial embolism occurring during systemic heparin therapy. Arch Surg 76 (1958) 219-225
29. Roberts B., Rosato F.E., and Rosato E.F. Heparin: a cause of arterial emboli?. Surgery 55 (1963) 803-808
30. Kelton J.G., and Warkentin T.E. Heparin-induced thrombocytopenia: a historical perspective. Blood 112 (2008) 2607-2615
31. Natelson E.A., Lynch E.C., Alfrey Jr. C.P., et al. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann Intern Med 71 (1969) 1121-1125
32. Rhodes G.R., Dixon R.H., and Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 136 (1973) 409-416
33. Rhodes G.R., Dixon R.H., and Silver D. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann Surg 186 (1977) 752-758
34. Chong B.H., and Berndt M.C. Heparin-induced thrombocytopenia. Blut 58 (1989) 53-57
35. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68 (1992) 95-96
36. Kelton J.G., Sheridan D., Santos A., et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 72 (1988) 925-930
37. Newman P.M., and Chong B.H. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 96 (2000) 182-187
38. Visentin G.P., Ford S.E., Scott J.P., et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93 (1994) 81-88
39. Warkentin T.E., Hayward C.P., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84 (1994) 3691-3699
40. Pouplard C., Iochmann S., Renard B., et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97 (2001) 3300-3302
41. Arepally G.M., and Mayer I.M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98 (2001) 1252-1254
42. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin induced thrombocytopenia: ACCP evidence-based clinical practice guidelines. Chest 133 Suppl (2008) 340S-380S
43. Davoren A., and Aster R.H. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 81 (2006) 36-44
44. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121 (2003) 535-555
45. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
46. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
47. Greinacher A., Farner B., Kroll H., et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94 (2005) 132-135
48. Boshkov L.K., Warkentin T.E., Hayward C.P.M., et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 84 (1993) 322-328
49. Hong A.P., Cook D.J., Sigouin C.S., et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101 (2003) 3049-3051
50. Linkins L.A., and Warkentin T.E. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 29 (2008) 66-74
51. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4 (2006) 759-765
52. Blank M., Shoenfeld Y., Tavor S., et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14 (2002) 121-129
53. Warkentin T.E., and Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 (2001) 502-506
54. Prechel M.M., McDonald M.K., Jeske W.P., et al. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 3 (2005) 2168-2175
55. Rauova L., Zhai L., Kowalska M.A., et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107 (2006) 2346-2353
56. Lo G.K., Sigouin C.S., and Warkentin T.E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 82 (2007) 1037-1043
57. Warkentin T.E., Sheppard J.A., Moore J.C., et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood (2009) in press
58. Sanders R.D., Carroll S.H., Jones T.A., et al. Is the new IgG enzyme-immunoassay for HIT a solution for our diagnostic dilemma?. Am J Clin Pathol 130 (2008) 491
59. Pouplard C., Amiral J., Borg J.Y., et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 111 (1999) 700-706
60. Zwicker J.I., Uhl L., Huang W.Y., et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2 (2004) 2133-2137
61. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 146 (2005) 341-346
62. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6 (2008) 1304-1312
63. Refaai M.A., Laposata M., and Van Cott E.M. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am J Clin Pathol 119 (2003) 61-65
64. Chan M., Malynn E., Shaz B., et al. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hematol 83 (2008) 212-217
65. Boshkov L.K., Kirby A., Shen I., et al. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. Ann Thorac Surg 81 (2006) S2355-S2359
66. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
67. Warkentin T.E., Sheppard J.A., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 (2000) 1703-1708
68. Francis J.L., Palmer III G.J., Moroose R., et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75 (2003) 17-22
69. Pötzsch B., Klövekorn W.-P., and Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343 (2000) 515